The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response - Scorecard - MDSpire
Advertisement
The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response
Clinical Scorecard: The Role of the Intratumoral Microbiome in Modulating Anti-Tumor Immunity, Cancer Outcomes, and Treatment Efficacy in the Tumor Microenvironment
At a Glance
Category
Detail
Condition
Key Mechanisms
Interactions between malignant cells, stromal cells, infiltrating immune cells, and intratumoral microbes, emphasizing the microbiome's role.
Target Population
Care Setting
Key Highlights
The intratumoral microbiome constitutes a fourth component of the tumor microenvironment (TME).
Specific TME profiles are associated with cancer prognosis and therapeutic response.
Dysbiosis of the intratumoral microbiome may correlate with worse cancer outcomes.
TME subtyping can inform treatment efficacy and patient response to immunotherapy.
Emerging evidence suggests that intratumoral microbes influence immune cell function.
Targeting the intratumoral microbiome may enhance therapeutic outcomes.
Guideline-Based Recommendations
Diagnosis
Consider the role of the intratumoral microbiome in cancer prognosis.
Management
Integrate intratumoral microbiome analysis into TME classification models, using specific biomarkers.
Monitoring & Follow-up
Monitor changes in the intratumoral microbiome to assess treatment response.
Risks
Dysbiosis of the intratumoral microbiome may lead to poorer treatment outcomes.
Patient & Prescribing Data
Understanding the intratumoral microbiome may enhance therapeutic strategies, particularly in immunotherapy.
Clinical Best Practices
Utilize TME subtyping to guide immunotherapy decisions.
Investigate the impact of intratumoral microbes on immune cell populations using specific assays.
